$970 Million is the total value of Logos Global Management LP's 66 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DSGN | DESIGN THERAPEUTICS INC | $59,359,000 | +45.7% | 2,772,501 | 0.0% | 6.12% | +108.4% | |
| OLMA | OLEMA PHARMACEUTICALS INC | $35,043,000 | -66.0% | 3,743,875 | 0.0% | 3.61% | -51.4% | |
| VERV | VERVE THERAPEUTICS INC | $16,343,000 | -21.6% | 443,265 | 0.0% | 1.69% | +12.3% | |
| ELDN | ELEDON PHARMACEUTICALS INC | $5,908,000 | -28.6% | 1,339,793 | 0.0% | 0.61% | +2.0% | |
| CGEM | CULLINAN ONCOLOGY INC | $4,450,000 | -31.6% | 288,458 | 0.0% | 0.46% | -2.1% | |
| IKNA | IKENA ONCOLOGY INC | $3,760,000 | -0.6% | 299,853 | 0.0% | 0.39% | +42.1% | |
| NUVALENT INC | $2,563,000 | -6.2% | 134,650 | 0.0% | 0.26% | +34.0% | ||
| SOMALOGIC INC | $2,333,000 | +4.3% | 200,493 | 0.0% | 0.24% | +49.7% | ||
| OMEGA THERAPEUTICS INC | $999,000 | -39.9% | 88,235 | 0.0% | 0.10% | -14.2% | ||
| NUVBWS | NUVATION BIO INC*w exp 07/07/202 | $126,000 | -28.8% | 66,666 | 0.0% | 0.01% | 0.0% | |
| MREO | MEREO BIOPHARMA GROUP PLCads | $75,000 | -34.2% | 46,984 | 0.0% | 0.01% | 0.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 14 | Q3 2023 | 12.6% |
| KARUNA THERAPEUTICS INC | 14 | Q3 2023 | 5.6% |
| ALX ONCOLOGY HLDGS INC | 13 | Q3 2023 | 23.3% |
| DYNE THERAPEUTICS INC | 13 | Q3 2023 | 4.9% |
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 12.4% |
| OLEMA PHARMACEUTICALS INC | 12 | Q3 2023 | 15.4% |
| DESIGN THERAPEUTICS INC | 11 | Q3 2023 | 8.0% |
| NUVATION BIO INC | 11 | Q3 2023 | 0.0% |
| BICYCLE THERAPEUTICS PLC | 10 | Q2 2023 | 5.7% |
| IDEAYA BIOSCIENCES INC | 9 | Q3 2023 | 9.5% |
View Logos Global Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 18, 2023 | 6,350,000 | 8.1% |
| BICYCLE THERAPEUTICS plc | February 14, 2023 | 1,435,000 | 4.8% |
| Dyne Therapeutics, Inc. | February 14, 2023 | 2,150,000 | 4.1% |
| Design Therapeutics, Inc. | March 31, 2022 | 2,797,501 | 5.0% |
| IDEAYA Biosciences, Inc. | March 18, 2022 | 2,650,000 | 6.9% |
| Aligos Therapeutics, Inc. | February 14, 2022 | ? | ? |
| Cogent Biosciences, Inc. | February 14, 2022 | 150,000 | 0.4% |
| Kezar Life Sciences, Inc. | February 14, 2022 | 1,450,000 | 3.0% |
| Nkarta, Inc. | February 14, 2022 | ? | ? |
| Viridian Therapeutics, Inc.\DE | February 14, 2022 | ? | ? |
View Logos Global Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-01 |
| SC 13G | 2024-02-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-02 |
View Logos Global Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.